|
|
Volumn 174, Issue 4, 2001, Pages 284-287
|
|
Medicine cabinet: Adjuvant therapy for breast cancer: Who should get what?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOTOXIC AGENT;
TAMOXIFEN CITRATE;
ANTINEOPLASTIC AGENT;
TAMOXIFEN;
AXILLARY LYMPH NODE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
FEMALE;
HORMONE SENSITIVITY;
HUMAN;
LYMPH NODE METASTASIS;
MORBIDITY;
PRIMARY MEDICAL CARE;
QUALITY OF LIFE;
REVIEW;
TREATMENT PLANNING;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
BREAST TUMOR;
METHODOLOGY;
MORTALITY;
PATIENT SELECTION;
PROGNOSIS;
SURVIVAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
FEMALE;
HUMANS;
PATIENT SELECTION;
PROGNOSIS;
RADIOTHERAPY, ADJUVANT;
SURVIVAL ANALYSIS;
TAMOXIFEN;
TREATMENT OUTCOME;
|
|
EID: 0035321053
PISSN: 00930415
EISSN: None
Source Type: Journal
DOI: 10.1136/ewjm.174.4.284 Document Type: Review |
|
Times cited : (52)
|
|
References (11)
|
